Skip to main content
Back
Watch Compare

CASI Pharmaceuticals, Inc.

Data quality: 100%
CASIF
OTC Manufacturing Chemicals
$0.12
▼ $0.00 (-0.74%)
Mkt Cap: 2.50 M
Price
$0.12
Mkt Cap
2.50 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Debt/Equity of 10.21 — high leverage
Negative free cash flow of -29.45 M
Capital efficient — spends only 0.78% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-15.77%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-301.80%
Below sector avg (-53.34%)
ROIC-82.63%
Net Margin-137.57%
Op. Margin-138.84%

Safety

Debt / Equity
10.21
Above sector avg (0.31)
Current Ratio1.09
Interest CoverageN/A

Valuation

PE (TTM)
-0.06
Above sector avg (-1.47)
P/B Ratio1.35
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.1 -1.5
P/B 1.4 1.6
ROE % -301.8 -53.3
Net Margin % -137.6 -41.5
Rev Growth 5Y % — 1.8
D/E 10.2 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -15.77% Revenue Growth (3Y) -18.64%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 28.54 M Net Income (TTM) -39.26 M
ROE -301.80% ROA -60.89%
Gross Margin 39.06% Operating Margin -138.84%
Net Margin -137.57% Free Cash Flow (TTM) -29.45 M
ROIC -82.63% FCF Growth (3Y) N/A
Safety
Debt / Equity 10.21 Current Ratio 1.09
Interest Coverage N/A Asset Turnover 0.44
Working Capital 3.12 M Tangible Book Value 1.61 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.06 Forward P/E N/A
P/B Ratio 1.35 P/S Ratio 0.09
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1175.61%
Market Cap 2.50 M Enterprise Value 7.93 M
Per Share
EPS (Diluted TTM) -2.56 Revenue / Share 1.39
FCF / Share -1.43 OCF / Share -1.42
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.78% FCF Conversion 75.01%
SBC-Adj. FCF -30.75 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022
Revenue 28.54 M 33.88 M 43.11 M
Net Income -39.26 M -26.96 M -41.01 M
EPS (Diluted) -2.56 -2.02 -3.01
Gross Profit 11.15 M 20.05 M 27.28 M
Operating Income -39.62 M -25.08 M -34.03 M
EBITDA — — —
R&D Expenses 8.92 M — —
SG&A Expenses — — —
D&A 1.30 M 2.50 M 1.20 M
Interest Expense — 614,000.0 0.0
Income Tax 0.0 -81,000.0 1.98 M

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022
Total Assets 53.67 M 75.27 M 96.23 M
Total Liabilities 51.82 M 51.10 M 29.30 M
Shareholders' Equity 1.85 M 24.17 M 44.57 M
Total Debt 18.90 M 18.90 M —
Cash & Equivalents 13.47 M 17.08 M 47.11 M
Current Assets 39.58 M 59.34 M 73.42 M
Current Liabilities 36.45 M 16.73 M 17.01 M